Ziyi Xu

Beijing, 100124, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Metal-Organic Frameworks (MOFs)-Derived Mesoporous Carbon Encapsulated Ultrafine Scandium Oxide Electrocatalyst for Highly Efficient Oxidation of 5-Hydroxymethylfurfural to 2,5-Furandicarboxylic Acid.

Metal-Organic Frameworks (MOFs)-Derived Mesoporous Carbon Encapsulated Ultrafine Scandium Oxide Electrocatalyst for Highly Efficient Oxidation of 5-Hydroxymethylfurfural to 2,5-Furandicarboxylic Acid.

Journal: Small methods

Published: March 02, 2025

Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.

Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.

Journal: Chinese medical journal

Published: May 10, 2023

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.

Journal: BMC cancer

Published: November 18, 2022

Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives.

Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives.

Journal: Cancer innovation

Published: November 02, 2022

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report.

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report.

Journal: Frontiers in oncology

Published: May 06, 2022

Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.

Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.

Journal: Thoracic cancer

Published: April 17, 2022

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression.

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression.

Journal: Cancer management and research

Published: February 21, 2022

Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.

Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.

Journal: BMC cancer

Published: January 23, 2022

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients.

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients.

Journal: Cancer management and research

Published: October 25, 2021

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.

Journal: Journal of cancer research and clinical oncology

Published: September 26, 2021

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.

Journal: Thoracic cancer

Published: July 14, 2021

Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.

Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.

Journal: Thoracic cancer

Published: July 05, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026